Origins of leukaemia in children with Down syndrome (original) (raw)

• Ross, J. A., Spector, L. G., Robison, L. L. & Olshan, A. F. Epidemiology of leukemia in children with Down syndrome. Pediatr. Blood Cancer 44, 8–12 (2005)
  Article PubMed Google Scholar
• Fong, C. T. & Brodeur, G. M. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet. Cytogenet. 28, 55–76 (1987).
  Article CAS PubMed Google Scholar
• Avet-Loiseau, H., Mechinaud, F. & Harousseau, J. L. Clonal hematologic disorders in Down syndrome. A review. J. Pediatr. Hematol. Oncol. 17, 19–24 (1995).
  Article CAS PubMed Google Scholar
• Satge, D. et al. A tumor profile in Down syndrome. Am. J. Med. Genet. 78, 207–216 (1998).
  Article CAS PubMed Google Scholar
• Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355, 165–169 (2000). Population-based overview of the frequencies of leukaemic and non-leukaemic malignant disorders in DS highlighting the association with an increased risk of leukaemia and a decreased incidence of solid tumours.
  Article CAS PubMed Google Scholar
• Hasle, H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2, 429–436 (2001).
  Article CAS PubMed Google Scholar
• Bennett, J. M. et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French–American–British Cooperative Group. Ann. Intern. Med. 103, 460–462 (1985).
  Article CAS PubMed Google Scholar
• Zipursky, A., Poon, A. & Doyle, J. Leukemia in Down syndrome: a review. Pediatr. Hematol. Oncol. 9, 139–149 (1992).
  Article CAS PubMed Google Scholar
• Wechsler, J. et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genet. 32, 148–152 (2002). First demonstration that somatic mutations of GATA1 resulting in the expression of a mutant protein truncated at the amino terminus are specific for AMKL of DS.
  Article CAS PubMed Google Scholar
• Lange, B. J. et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 91, 608–615 (1998).
  CAS PubMed Google Scholar
• Zipursky, A., Thorner, P., De Harven, E., Christensen, H. & Doyle, J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk. Res. 18, 163–171 (1994).
  Article CAS PubMed Google Scholar
• Zipursky, A. Transient leukaemia — a benign form of leukaemia in newborn infants with trisomy 21. Br. J. Haematol. 120, 930–938 (2003). Recent review of the clinical, cellular and molecular features of TL as a unique reversible disorder that precedes AMKL in DS.
  Article PubMed Google Scholar
• Kurahashi, H. et al. Monoclonal nature of transient abnormal myelopoiesis in Down's syndrome. Blood 77, 1161–1163 (1991).
  Article CAS PubMed Google Scholar
• Miyashita, T. et al. Clonal analysis of transient myeloproliferative disorder in Down's syndrome. Leukemia 5, 56–59 (1991).
  CAS PubMed Google Scholar
• Shimada, A. et al. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Blood 103, 366 (2004).
  Article CAS PubMed Google Scholar
• Al-Kasim, F., Doyle, J. J., Massey, G. V., Weinstein, H. J. & Zipursky, A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J. Pediatr. Hematol. Oncol. 24, 9–13 (2002).
  Article PubMed Google Scholar
• Dormann, S. et al. Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome. Eur. J. Pediatr. 163, 374–377 (2004).
  Article CAS PubMed Google Scholar
• Tchernia, G. et al. Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low-dose arabinosyl cytosine. J. Pediatr. Hematol. Oncol. 18, 59–62 (1996).
  Article CAS PubMed Google Scholar
• Zipursky, A., Rose, T., Skidmore, M., Thorner, P. & Doyle, J. Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatr. Hematol. Oncol. 13, 81–87 (1996).
  Article CAS PubMed Google Scholar
• Miyauchi, J., Ito, Y., Kawano, T., Tsunematsu, Y. & Shimizu, K. Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down's syndrome: a report of four autopsy cases and proposal of a hypothesis. Blood 80, 1521–1527 (1992).
  Article CAS PubMed Google Scholar
• Gamis, A. S. & Hilden, J. M. Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? J. Pediatr. Hematol. Oncol. 24, 2–5 (2002).
  Article PubMed Google Scholar
• Clark, S., Nathan, D. G. & Sieff, C. in Nathan and Oski's Hematology of Infancy and Childhood 6th edn (eds Nathan, D., Orkin, S., Ginsburg, D. & Look, A.) 171–255 (2003).
  Google Scholar
• Israels, S. J., Rand, M. L. & Michelson, A. D. Neonatal platelet function. Semin. Thromb. Hemost. 29, 363–372 (2003).
  Article CAS PubMed Google Scholar
• Ma, S. K., Lee, A. C., Wan, T. S., Lam, C. K. & Chan, L. C. Trisomy 8 as a secondary genetic change in acute megakaryoblastic leukemia associated with Down's syndrome. Leukemia 13, 491–492 (1999).
  Article CAS PubMed Google Scholar
• Duflos-Delaplace, D. et al. Transient leukemoid disorder in a newborn with Down syndrome followed 19 months later by an acute myeloid leukemia: demonstration of the same structural change in both instances with clonal evolution. Cancer Genet. Cytogenet. 113, 166–171 (1999).
  Article CAS PubMed Google Scholar
• Polski, J. M. et al. Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate. J. Pediatr. Hematol. Oncol. 24, 50–54 (2002).
  Article PubMed Google Scholar
• Hayashi, Y. et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood 72, 15–23 (1988).
  Article CAS PubMed Google Scholar
• Ahmed, M. et al. Natural history of GATA1 mutations in Down Syndrome. Blood 103, 2480–2489 (2004).
  Article CAS PubMed Google Scholar
• Zipursky, A., Christensen, H. & De Harven, E. Ultrastructural studies of the megakaryoblastic leukemias of Down syndrome. Leuk. Lymphoma 18, 341–347 (1995).
  Article CAS PubMed Google Scholar
• Eguchi, M. et al. Ultrastructural and ultracytochemical differences between transient myeloproliferative disorder and megakaryoblastic leukaemia in Down's syndrome. Br. J. Haematol. 73, 315–322 (1989).
  Article CAS PubMed Google Scholar
• Slordahl, S. H. et al. Leukemic blasts with markers of four cell lineages in Down's syndrome ('megakaryoblastic leukemia'). Med. Pediatr. Oncol. 21, 254–258 (1993).
  Article CAS PubMed Google Scholar
• Bozner, P. Transient myeloproliferative disorder with erythroid differentiation in Down syndrome. Arch. Pathol. Lab. Med. 126, 474–477 (2002).
  Article PubMed Google Scholar
• Vanhaeke, D., Vainchenker, W., Yver, A. & Leverger, G. [A case of erythoblastic leukemia with basophilic reaction]. Presse Med. 20, 267 (1991).
  CAS PubMed Google Scholar
• Ito, E. et al. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome. Br. J. Haematol. 90, 607–614 (1995).
  Article CAS PubMed Google Scholar
• Suda, J. et al. Differentiation of blast cells from a Down's syndrome patient with transient myeloproliferative disorder. Blood 69, 508–512 (1987).
  Article CAS PubMed Google Scholar
• Suda, T. et al. Clonal analysis of basophil differentiation in bone marrow cultures from a Down's syndrome patient with megakaryoblastic leukemia. Blood 66, 1278–1283 (1985).
  Article CAS PubMed Google Scholar
• Worth, L. L., Zipursky, A., Christensen, H. & Tubergen, D. Transient leukemia with extreme basophilia in a phenotypically normal infant with blast cells containing a pseudodiploid clone, 46,XY i(21)(q10). J. Pediatr. Hematol. Oncol. 21, 63–66 (1999).
  Article CAS PubMed Google Scholar
• Cantor, A. B. & Orkin, S. H. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 21, 3368–3376 (2002).
  Article CAS PubMed Google Scholar
• Kulessa, H., Frampton, J. & Graf, T. GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts. Genes Dev. 9, 1250–1262 (1995).
  Article CAS PubMed Google Scholar
• Orkin, S. H., Shivdasani, R. A., Fujiwara, Y. & McDevitt, M. A. Transcription factor GATA-1 in megakaryocyte development. Stem Cells 16 (Suppl. 2), 79–83 (1998).
  PubMed Google Scholar
• Tsang, A. P. et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 90, 109–119 (1997).
  Article CAS PubMed Google Scholar
• Shivdasani, R. A. et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81, 695–704 (1995).
  Article CAS PubMed Google Scholar
• Hart, A. et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 13, 167–177 (2000).
  Article CAS PubMed Google Scholar
• Saleque, S., Cameron, S. & Orkin, S. H. The zinc-finger proto-oncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages. Genes Dev. 16, 301–306 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Matsumura, I. & Kanakura, Y. Molecular control of megakaryopoiesis and thrombopoiesis. Int. J. Hematol. 75, 473–483 (2002).
  Article CAS PubMed Google Scholar
• Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G. & Downing, J. R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321–330 (1996).
  Article CAS PubMed Google Scholar
• Wang, Q. et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. PNAS 93, 3444–3449 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Elagib, K. E. et al. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 101, 4333–4341 (2003).
  Article CAS PubMed Google Scholar
• Tsai, S. F. et al. Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature 339, 446–451 (1989).
  Article CAS PubMed Google Scholar
• Evans, T. & Felsenfeld, G. The erythroid-specific transcription factor Eryf1: a new finger protein. Cell 58, 877–885 (1989).
  Article CAS PubMed Google Scholar
• Martin, D. I., Zon, L. I., Mutter, G. & Orkin, S. H. Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature 344, 444–447 (1990).
  Article CAS PubMed Google Scholar
• Romeo, P. H. et al. Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature 344, 447–449 (1990).
  Article CAS PubMed Google Scholar
• Zon, L. I. et al. Expression of mRNA for the GATA-binding proteins in human eosinophils and basophils: potential role in gene transcription. Blood 81, 3234–3241 (1993).
  Article CAS PubMed Google Scholar
• Hirasawa, R. et al. Essential and instructive roles of GATA factors in eosinophil development. J. Exp. Med. 195, 1379–1386 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, C. et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J. Exp. Med. 195, 1387–1395 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Migliaccio, A. R. et al. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. J. Exp. Med. 197, 281–296 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Visvader, J. E., Elefanty, A. G., Strasser, A. & Adams, J. M. GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. EMBO J. 11, 4557–4564 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Yamaguchi, Y., Zon, L. I., Ackerman, S. J., Yamamoto, M. & Suda, T. Forced GATA-1 expression in the murine myeloid cell line M1: induction of c-Mpl expression and megakaryocytic/erythroid differentiation. Blood 91, 450–457 (1998).
  Article CAS PubMed Google Scholar
• Fujiwara, Y., Browne, C. P., Cunniff, K., Goff, S. C. & Orkin, S. H. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc. Natl Acad. Sci. USA 93, 12355–12358 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Shivdasani, R. A., Fujiwara, Y., McDevitt, M. A. & Orkin, S. H. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 16, 3965–3973 (1997). Description of the effects of GATA1 deficiency in the cells of megakaryocytic lineage in an in vivo model that has phenotypic similarities with TL of DS.
  Article CAS PubMed PubMed Central Google Scholar
• Vyas, P., Ault, K., Jackson, C. W., Orkin, S. H. & Shivdasani, R. A. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 93, 2867–2875 (1999).
  Article CAS PubMed Google Scholar
• Gurbuxani, S., Vyas, P. & Crispino, J. D. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 103, 399–406 (2004). Comprehensive review of currently available models of decreased haematopoietic GATA1 function in vivo and the effects on megakaryocytic differentiation.
  Article CAS PubMed Google Scholar
• Takahashi, S. et al. Role of GATA-1 in proliferation and differentiation of definitive erythroid and megakaryocytic cells in vivo. Blood 92, 434–442 (1998).
  Article CAS PubMed Google Scholar
• Vannucchi, A. M. et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1low mice). Blood 100, 1123–1132 (2002).
  Article CAS PubMed Google Scholar
• Cripe, L. & Hromas, R. Malignant disorders of megakaryocytes. Semin. Hematol. 35, 200–209 (1998).
  CAS PubMed Google Scholar
• Nichols, K. E. et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nature Genet. 24, 266–270 (2000).
  Article CAS PubMed Google Scholar
• Freson, K. et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 98, 85–92 (2001).
  Article CAS PubMed Google Scholar
• Mehaffey, M. G., Newton, A. L., Gandhi, M. J., Crossley, M. & Drachman, J. G. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood 98, 2681–2688 (2001).
  Article CAS PubMed Google Scholar
• Yu, C. et al. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 100, 2040–2045 (2002).
  Article CAS PubMed Google Scholar
• Crispino, J. D. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr. Blood Cancer 44, 40–44 (2005).
  Article PubMed Google Scholar
• Rainis, L. et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 102, 981–986 (2003).
  Article CAS PubMed Google Scholar
• Hitzler, J. K., Cheung, J., Li, Y., Scherer, S. W. & Zipursky, A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 101, 4301–4304 (2003).
  Article CAS PubMed Google Scholar
• Xu, G. et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102, 2960–2968 (2003).
  Article CAS PubMed Google Scholar
• Harigae, H. et al. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood 103, 3242–3243 (2004).
  Article CAS PubMed Google Scholar
• Taub, J. W. & Ge, Y. Down syndrome, drug metabolism and chromosome 21. Pediatr. Blood Cancer 44, 33–39 (2005).
  Article PubMed Google Scholar
• Ge, Y. et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res. 64, 728–735 (2004). Update on the unique pharmacological sensitivity of the blasts in (non-lymphoid) leukaemia of DS with reference to previous work in this area.
  Article CAS PubMed Google Scholar
• Groet, J. et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 361, 1617–1620 (2003).
  Article CAS PubMed Google Scholar
• Mundschau, G. et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 101, 4298–4300 (2003).
  Article CAS PubMed Google Scholar
• Taub, J. W. et al. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 104, 1588–1589 (2004).
  Article CAS PubMed Google Scholar
• Rylski, M. et al. GATA-1-mediated proliferation arrest during erythroid maturation. Mol. Cell. Biol. 23, 5031–5042 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• McElwaine, S. et al. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br. J. Haematol. 125, 729–742 (2004).
  Article CAS PubMed Google Scholar
• Lightfoot, J., Hitzler, J., Zipursky, A., Albert, M. & Macgregor, P. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia 18, 1617–1623 (2004).
  Article CAS PubMed Google Scholar
• Calligaris, R., Bottardi, S., Cogoi, S., Apezteguia, I. & Santoro, C. Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Proc. Natl Acad. Sci. USA 92, 11598–11602 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Shimizu, R., Takahashi, S., Ohneda, K., Engel, J. D. & Yamamoto, M. In vivo requirements for GATA-1 functional domains during primitive and definitive erythropoiesis. EMBO J. 20, 5250–5260 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Speck, N. A. & Gilliland, D. G. Core-binding factors in haematopoiesis and leukaemia. Nature Rev. Cancer 2, 502–513 (2002).
  Article CAS Google Scholar
• Ichikawa, M. et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nature Med. 10, 299–304 (2004).
  Article CAS PubMed Google Scholar
• Song, W. J. et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genet. 23, 166–175 (1999).
  Article CAS PubMed Google Scholar
• Waltzer, L., Ferjoux, G., Bataille, L. & Haenlin, M. Cooperation between the GATA and RUNX factors Serpent and Lozenge during Drosophila hematopoiesis. EMBO J. 22, 6516–6525 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Gilliland, D. G. & Tallman, M. S. Focus on acute leukemias. Cancer Cell 1, 417–420 (2002).
  Article CAS PubMed Google Scholar
• Izraeli, S. Leukaemia — a developmental perspective. Br. J. Haematol. 126, 3–10 (2004).
  Article CAS PubMed Google Scholar
• Hattori, M. et al. The DNA sequence of human chromosome 21. Nature 405, 311–319 (2000).
  Article CAS PubMed Google Scholar
• Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A. & Deutsch, S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nature Rev. Genet. 5, 725–738 (2004).
  Article CAS PubMed Google Scholar
• Gitton, Y. et al. A gene expression map of human chromosome 21 orthologues in the mouse. Nature 420, 586–590 (2002).
  Article CAS PubMed Google Scholar
• Reymond, A. et al. Human chromosome 21 gene expression atlas in the mouse. Nature 420, 582–586 (2002).
  Article CAS PubMed Google Scholar
• Korenberg, J. R. et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl Acad. Sci. USA 91, 4997–5001 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Kola, I. & Hertzog, P. J. Down syndrome and mouse models. Curr. Opin. Genet. Dev. 8, 316–321 (1998).
  Article CAS PubMed Google Scholar
• Epstein, C. J., Cox, D. R. & Epstein, L. B. Mouse trisomy 16: an animal model of human trisomy 21 (Down syndrome). Ann. NY Acad. Sci. 450, 157–168 (1985).
  Article CAS PubMed Google Scholar
• Roizen, N. J. & Patterson, D. Down's syndrome. Lancet 361, 1281–1289 (2003).
  Article PubMed Google Scholar
• Jones, K. Smith's Recognizable Patterns of Human Malformation 4th edn 10–15 (W. B. Saunders Company, Philadelphia, 1988).
  Google Scholar
• Down, J. Observations on an ethnic classification of idiots. London Hosp. Clin. Lect. Rep. 259 (1866).
• Lejeune, J., Gautier, M. & Turpin, R. Etude des chromosomes somatiques de neuf enfants mongoliens. C.R. Acad. Sci. 248, 1721–1722 (1959).
  CAS Google Scholar
• Ravindranath, Y. Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J. Clin. Oncol. 21, 3385–3387 (2003).
  Article PubMed Google Scholar
• Ravindranath, Y. et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 80, 2210–2214 (1992).
  Article CAS PubMed Google Scholar
• Gamis, A. S. et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J. Clin. Oncol. 21, 3415–3422 (2003).
  Article PubMed Google Scholar
• Taub, J. W. et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 94, 1393–1400 (1999).
  CAS PubMed Google Scholar
• Taub, J. W. et al. Enhanced metabolism of 1-β-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 87, 3395–3403 (1996).
  Article CAS PubMed Google Scholar
• Zipursky, A. The treatment of children with acute megakaryoblastic leukemia who have Down syndrome. J. Pediatr. Hematol. Oncol. 18, 10–12 (1996).
  Article Google Scholar
• Arai, H. et al. Immunohistochemical study on transforming growth factor-β1 expression in liver fibrosis of Down's syndrome with transient abnormal myelopoiesis. Hum. Pathol. 30, 474–476 (1999).
  Article CAS PubMed Google Scholar
• Hattori, H. et al. High expression of platelet-derived growth factor and transforming growth factor-β1 in blast cells from patients with Down Syndrome suffering from transient myeloproliferative disorder and organ fibrosis. Br. J. Haematol. 115, 472–475 (2001).
  Article CAS PubMed Google Scholar
• Greaves, M. F. & Wiemel, J. Origins of chromosome translocations in childhood leukaemia. Nature Rev. Cancer 3, 639–649 (2003).
  Article CAS Google Scholar
• Trainor, C. D. et al. A palindromic regulatory site within vertebrate GATA-1 promoters requires both zinc fingers of the GATA-1 DNA-binding domain for high-affinity interaction. Mol. Cell. Biol. 16, 2238–2247 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Hasle, H. et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17, 277–282 (2003).
  Article CAS PubMed Google Scholar
• Creutzig, U. et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM study group. Leukemia 10, 1677–1686 (1996).
  CAS PubMed Google Scholar